Oral News and Research

RSS

BioScrip announces revenues of $341.6M for fourth-quarter

BioScrip, Inc. today announced fourth quarter revenues of $341.6 million and net income of $40.7 million, or $0.99 per diluted share, which includes the reversal of the Company’s deferred tax valuation allowance of $41.1 million, expenses of $1.8 million associated with BioScrip’s pending acquisition of Critical Homecare Solutions, Inc. and $4.3 million of incentive compensation expense relating to the Company’s employee compensation program.

26 Feb 2010

Remedent and Precise Structures Milling Center named as SensAble Authorized Milling Centers

SensAble Technologies, Inc®, a leading provider of 3D touch-enabled modeling solutions, dental CAD/CAM solutions and haptic devices, has announced partnerships with key dental industry players that will offer fabrication services for milled crowns and bridges, in a variety of materials including zirconia, to SensAble Dental Lab System owners. Partners include Remedent Inc., of Ghent, Belgium, an international leader in oral care and cosmetic dentistry products; and Precise Structures Milling Center of Laguna Hills CA, which operates milling centers in Laguna Hills and Oshawa, Ontario.

26 Feb 2010

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Using an accelerated, shorter course of radiation therapy for patients with advanced head and neck cancer allows doctors to reduce the amount of chemotherapy, thus reducing toxicity, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.

26 Feb 2010

Genta initiates new dose-ranging study of tesetaxel drug

Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

26 Feb 2010

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.

26 Feb 2010

Pew's report highlights need for effective oral health delivery system

"We welcome the Pew organization to our longstanding fight to improve the lives of American children by helping more of them enjoy the good oral health that too many of them now lack.

25 Feb 2010

Delta Dental launches community grant program to promote oral health

Since 1965 when the Tennessee General Assembly passed legislation enabling its creation, Delta Dental of Tennessee has been committed to advancing and promoting the improvement of oral health in Tennessee.

25 Feb 2010

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Today, GlaxoSmithKline responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report").

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

Pain-free sedation dentistry may help reduce fear of the dentist

Fear of the dentist is a huge problem in the United States. While as many as four out of five Americans admit being afraid of the dentist, it is estimated that one in seven Americans never get any dental treatment at all because of dental phobia. Sedation dentistry is a pain-free option.

24 Feb 2010

Emerging oral atypical antipsychotics to compete in increasingly crowded schizophrenia drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the world's major pharmaceutical markets, emerging oral atypical antipsychotics will compete against each other and against established drugs for the same niche patient population in the treatment of schizophrenia.

24 Feb 2010

Study may help in defining better therapeutic strategies for oral and throat cancer

Mayo Clinic researchers along with collaborators from Life Technologies are reporting on the application of a new approach for sequencing RNA to study cancer tumors. Their findings from a proof-of-principle study on oral carcinomas appear in the current issue of PLoS One, the online science journal.

24 Feb 2010

Presence of SIBLING proteins in premalignant oral lesions may predict oral cancer

The presence of certain proteins in premalignant oral lesions may predict oral cancer development, Medical College of Georgia researchers said.

24 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

WuXi PharmaTech (WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it received the formal certificate of GMP compliance from the Medical Products Agency (MPA) of Sweden, acting on behalf of the European Medicines Agency (EMEA), for its c-GMP drug product manufacturing and analytical testing facilities located in Shanghai.

24 Feb 2010

Also in global health news: Global Fund; MDGs, women; polio eradication

Radio Australia examines the Global Fund to Fight AIDS, Tuberculosis and Malaria's push for more funding from Australia and China. Global Fund Executive Director "Michel Kazatchkine is currently touring the world's capitals seeking renewed government pledges to build on an already impressive record and as well as looking to Australia to do more, he's hoping soon to get China to become not just recipient, but donor."

24 Feb 2010

Findings suggest bitter melon extract may help in preventing breast cancer

Bitter melon extract, a common dietary supplement, exerts a significant effect against breast cancer cell growth and may eventually become a chemopreventive agent against this form of cancer, according to results of a recent study.

23 Feb 2010

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Salix Pharmaceuticals, Ltd. today announced that NASDAQ has halted trading of the Company’s common stock this morning. The Gastrointestinal Drugs Advisory Committee of the FDA is meeting today to discuss the efficacy and safety of the New Drug Application (NDA) for XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy.

23 Feb 2010

Solta Medical announces definitive agreement to acquire Aesthera

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.

23 Feb 2010

Oral News and Research

BioScrip announces revenues of $341.6M for fourth-quarter

Remedent and Precise Structures Milling Center named as SensAble Authorized Milling Centers

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Genta initiates new dose-ranging study of tesetaxel drug

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Pew's report highlights need for effective oral health delivery system

Delta Dental launches community grant program to promote oral health

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Pain-free sedation dentistry may help reduce fear of the dentist

Emerging oral atypical antipsychotics to compete in increasingly crowded schizophrenia drug market

Study may help in defining better therapeutic strategies for oral and throat cancer

Presence of SIBLING proteins in premalignant oral lesions may predict oral cancer

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

Also in global health news: Global Fund; MDGs, women; polio eradication

Findings suggest bitter melon extract may help in preventing breast cancer

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Solta Medical announces definitive agreement to acquire Aesthera

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News